Alan Lichtin is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 170 publications with 7,590 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441950001
Telephone
800-223-2273Registry record last updated 1 Feb 2008.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20232 payments
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year20231 payment
- ARGENX US, INC.Program year202210 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35%Antimetabolite21.3%Hydroxyurea100%Part D≥25 patientsKinase inhibitor11%Jakafi71%Imatinib Mesylate29%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
26.4%Corticosteroid12.9%Prednisone100%Part D≥22 patientsHydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme5.5%Fabrazyme100%Part D<11 patients+ 3 more classes in this area
Blood & clotting
26.4%Factor Xa inhibitor17.5%Eliquis70%Xarelto30%Part D<11 patientsVitamin K antagonist6.5%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
British Journal of Haematology
2019 - Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)
Leukemia & lymphoma/Leukemia and lymphoma
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Arthur McCullough, MD
Cleveland Clinic
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”